Related Experiment Video
Updated: Aug 1, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate cancer gene therapy
1The James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21287-2101, USA.
Abstract:
Cancer-specific gene therapy is still in its infancy. Although the first gene therapy trials were initiated in the late 1980s, it was only more recently that the first successful treatment of a genetic disease was reported.3 The current problems with low efficiency of gene transfer coupled with the immunologic difficulties with certain vectors indicate that more effort needs to be directed at the basic science of gene transfer. Ultimately, successful cancer-specific gene therapy will require combinations of the lessons learned from the ex vivo and in vivo paradigms. The next generation of gene therapy trials likely will focus on combination therapy with conventional chemotherapeutic agents, differentiating agents, or radiation therapy. The obstacles to the development of gene-based human therapeutics (i.e., molecular medicine) are formidable, but the benefits are so great that eventually the technical issues of gene transfer methodology will be worked out, and ultimately this will become the standard of care, not only for inborn errors of metabolism, but also for cancer.
Insights
Cancer gene therapy shows promise but faces challenges in gene transfer efficiency and vector immunogenicity. Future research will focus on combination therapies, aiming to make gene therapy a standard cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Cancer-specific gene therapy is an emerging field with early-stage development.
- Despite initial trials in the late 1980s, significant progress has been slow.
- Recent successes in treating genetic diseases highlight gene therapy's potential.
Purpose of the Study:
- To address the current limitations in cancer-specific gene therapy.
- To explore the future directions and potential of gene therapy in oncology.
- To emphasize the need for advancements in gene transfer technology.
Main Methods:
- Review of existing gene therapy paradigms (ex vivo and in vivo).
- Discussion of challenges including gene transfer efficiency and vector immunogenicity.
- Exploration of combination therapy strategies with conventional treatments.
Main Results:
- Current gene transfer methods face efficiency and immunological hurdles.
- Successful cancer gene therapy will likely integrate ex vivo and in vivo approaches.
- Future trials are expected to combine gene therapy with chemotherapy, differentiating agents, or radiation.
Conclusions:
- Overcoming technical obstacles in gene transfer is crucial for advancing gene therapy.
- Gene therapy holds significant potential to become a standard treatment for cancer.
- The development of gene-based therapeutics (molecular medicine) is a formidable but achievable goal.
Related Concept Videos
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...